Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM

Detalhes bibliográficos
Autor: Espinosa Arranz, Enrique
Formato: artículo
Fecha de publicación:2026
País:España
Recursos:Universidad Loyola Andalucía
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:dnet:biblosearchi::ae05eba072b9ca60b36abad2fbdad9f9
Acesso em linha:https://hdl.handle.net/10486/767401
https://dx.doi.org/10.1007/s00262-026-04392-1
Access Level:acceso abierto
Palavra-chave:Melanoma
Immunotherapy
Immune signature
Response to treatment
Medicina
id ES_6bdfeefe5f92ab7e78d3774f65f6db2a
oai_identifier_str oai:dnet:biblosearchi::ae05eba072b9ca60b36abad2fbdad9f9
network_acronym_str ES
network_name_str España
repository_id_str
spelling Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapyEspinosa Arranz, EnriqueMelanomaImmunotherapyImmune signatureResponse to treatmentMedicinaArtículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAMBackground Immunotherapy based on anti-PD1 inhibitors has significantly improved survival in advanced melanoma. However, a significant proportion of patients do not benefit, and predicting response to immunotherapy remains an area of unmet need. Our group previously defined an immune signature able to predict response to anti-PD1 inhibitors in this scenario. Methods In this study, we analyzed two cohorts of patients with advanced melanoma treated with anti-PD1 inhibitors: the GEM cohort, previously used to validate our immune signature, and Campbell’s cohort, which contains data about different immunotherapy schemes. Using the 107 genes that compose our immune signature and consensus clustering, samples were classified as immune-low or immune-high. Then, CIBERSORTx and Ecotyper were used to estimate the proportion of each immune cell type and carcinoma ecotypes in both cohorts. Results We confirmed that the immune-low group includes mostly patients who do not response to anti-PD1 inhibitors. We also studied the distribution of carcinoma ecotypes in the immune-high and immune-low groups defined by our immune classification. Ecotypes CE9 and CE10 clustered in the immune-high group, with good response to treatment. The use of combination immunotherapy improved response rate both in immune-low and immune-high tumors. The immune-high group contained a higher number of CD8 T cells, B memory cells and T follicular helper cells. Conclusions Our immune-based classification defines an immune-low group of tumors with poor response to anti-PD1 inhibitors. This immune classification is related to carcinoma ecotypes. Finally, a use of a combo scheme improves the rates of response both in immune-high and low groups but in the case of immune-low tumors, our results suggests that a combo treatment approach could be an adequate strategy and should be further explored in these patients. Altogether, our results support the utility of our immune signature in the prediction of response to anti-PD1 inhibitors in advanced melanoma.This work was supported by a grant from GEM (Spanish Melanoma Group).SpringerDepartamento de MedicinaFacultad de Medicina20262026-04-26research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10486/767401https://dx.doi.org/10.1007/s00262-026-04392-1reponame:Biblos-e Archivo. Repositorio Institucional de la UAMinstname:Universidad Loyola AndalucíaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:dnet:biblosearchi::ae05eba072b9ca60b36abad2fbdad9f92026-06-23T12:46:27Z
dc.title.none.fl_str_mv Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
title Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
spellingShingle Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
Espinosa Arranz, Enrique
Melanoma
Immunotherapy
Immune signature
Response to treatment
Medicina
title_short Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
title_full Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
title_fullStr Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
title_full_unstemmed Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
title_sort Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
dc.creator.none.fl_str_mv Espinosa Arranz, Enrique
author Espinosa Arranz, Enrique
author_facet Espinosa Arranz, Enrique
author_role author
dc.contributor.none.fl_str_mv Departamento de Medicina
Facultad de Medicina
dc.subject.none.fl_str_mv Melanoma
Immunotherapy
Immune signature
Response to treatment
Medicina
topic Melanoma
Immunotherapy
Immune signature
Response to treatment
Medicina
description Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM
publishDate 2026
dc.date.none.fl_str_mv 2026
2026-04-26
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10486/767401
https://dx.doi.org/10.1007/s00262-026-04392-1
url https://hdl.handle.net/10486/767401
https://dx.doi.org/10.1007/s00262-026-04392-1
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Biblos-e Archivo. Repositorio Institucional de la UAM
instname:Universidad Loyola Andalucía
instname_str Universidad Loyola Andalucía
reponame_str Biblos-e Archivo. Repositorio Institucional de la UAM
collection Biblos-e Archivo. Repositorio Institucional de la UAM
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410228090437632
score 15,812429

Registos relacionados